Latest Indoles Stories

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., March 25, 2013 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Stivarga(®) (regorafenib) tablets for the treatment of patients with metastatic colorectal cancer (mCRC). In September 2012, Stivarga was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with mCRC who have been...

Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumors might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to a new study to be presented at the 28th Annual EAU Congress currently on-going in Milan. "The inactivation of the von Hippel-Lindau gene (VHL) is a common event in ccRCC and finally leads to the induction of HIF1α target genes such as CA9 and VEGF," write the authors....

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., Feb. 25, 2013 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the U.S. Food and Drug Administration (FDA) approved Bayer's Stivarga(®) (regorafenib) tablets to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.(1 )Stivarga...

EAST HANOVER, N.J., Nov. 28, 2012 /PRNewswire/ -- Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases. The American Society of Hematology (ASH) annual meeting in Atlanta, held December 8-11, will feature...

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial. The treatment of gastrointestinal stromal tumor, or GIST, even in its advanced metastatic stage, has been dramatically improved with two oral targeted drugs – imatinib (Gleevec) and...

THE WOODLANDS, Texas, Oct. 12, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line data from a recently completed Phase 2 study in carcinoid syndrome with telotristat etiprate. Results from the trial will be presented at the North American Neuroendocrine Tumor Society on Saturday, October 13, 2012 in San Diego, California. Carcinoid syndrome is a...

YARDLEY, Pa., Oct. 2, 2012 /PRNewswire/ -- OptiNose US Inc. today announced results of a study testing delivery of the migraine medicine sumatriptan with a novel device using OptiNose breath powered Bi-Directional(TM) nasal technology. In a direct comparison of drug absorption, the study found that OptiNose's sumatriptan product sent 62% more drug into the blood in the critical first 15 minutes than Imitrex(®) nasal spray (AUC (0-15) = 1.69 ng*hr/mL and 1.04 ng*hr/mL,...

Brain scans of individuals under the influence of so-called magic mushrooms have given scientists the clearest illustration yet as to how such psychedelic drugs can affect people, while also providing hope that the active ingredient in this substance could be used to help treat depression. In two separate studies announced Monday, researchers discovered that the ingredient in question, psilocybin, does not increase activities in areas of the brain that tend to be suppressed by...

Researchers from Johns Hopkins University School of Medicine studying psilocybin, the mind-altering chemical in “magic mushrooms,” found that the chemical may actually alter people’s personalities for a long period of time, ABC News is reporting. The study involved one high dose of psilocybin administered to 51 adult study participants and found that 30 of them underwent measurable personality changes lasting more than a year. The aspect of personality that changed is known as...

The hallucinogen found in "magic mushrooms" could be used to treat a variety of psychiatric disorders, including depression, anxiety and addiction, according to researchers working on a new study. The scientists, working at Johns Hopkins University School of Medicine have figured out the dose levels of the "sacred mushroom" chemical capable of yielding positive experiences, while minimizing the chance of negative reactions like those found in volunteers of the study, who were under constant,...